SCHEMBL23664688

SCHEMBL23664688

CC(C)C(=O)COCCCOC1CN(C(C)S)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18592285 0.89 — —
SCHEMBL22560667 0.84 SMN1; SMN2 (0.33) —
SCHEMBL20046545 0.82 SMN1; SMN2 (0.32) —
SCHEMBL22374672 0.81 — —
SCHEMBL20325214 0.78 — —
SCHEMBL22006751 0.77 NAAA (0.32) —
SCHEMBL22692331 0.76 — —
SCHEMBL21026323 0.73 — —
SCHEMBL17169728 0.69 TDP1 (0.45) —
SCHEMBL20233673 0.69 NPC1 (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 — — US disclosed
US-20210220475-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-07-22 — — US disclosed
Send feedback